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D
iarrhoeal diseases are still among the leading 
causes of childhood mortality in the world, con-
tributing to more than 800 000 deaths in children 
younger than 5 years of age in 2010 [1,2]. It is widely ac-
knowledged that a major portion of those deaths can be 
prevented if universal coverage of known effective inter-
ventions could be achieved [3,4]. However, recent evalua-
tions have shown that the uptake of those interventions is 
rather disappointing, with only a minority of all children 
with life–threatening episodes of diarrhoea in low– and 
middle–income countries having access to trained health 
care providers and receiving appropriate treatment [5–7]. 
Thus, novel diarrhoea control strategies that balance invest-
ments in scaling up of existing interventions and the de-
velopment of novel approaches, technologies and ideas are 
needed.
The importance of childhood diarrhoea as a global public 
health problem is in stark contrast to the size of the re-
search community focused on the issue and the amount of 
funding committed to studying the disease [8]. However, 
there have been several efforts in recent years that aimed 
An expert panel exercise was conducted to 
assess feasibility and potential effectiveness 
of 10 emerging health interventions against 
childhood diarrhoea. Twelve international 
experts were invited to take part in a CHNRI 
priority setting process. This group used 12 
different criteria relevant to successful devel-
opment and implementation of the emerging 
interventions, nine of which were retained in 
the final analysis. They showed most collec-
tive optimism towards developing household 
or community-level water treatment, fol-
lowed by sustainable, affordable latrine op-
tions; those two emerging interventions were 
followed by antibiotic therapy of Cryptospo-
ridium diarrhoea, and oral or transcutaneous 
enteric vaccine development.
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to mobilize the research community and encourage re-
search on childhood diarrhoea. Kosek et al. used the Child 
Health and Nutrition Research Initiative (CHNRI) meth-
odology to define research priorities that could immedi-
ately reduce the burden of disease [9]. This was followed 
by the World Health Organization's CHNRI exercise that 
defined research priorities to reduce global mortality from 
childhood diarrhoea by the year 2015, ie, the time of the 
fourth Millennium Development Goal's target [10]. Recent-
ly, a new initiative has been launched – Global Action Plan 
for Pneumonia and Diarrhoea (GAPPD) – which prioritiz-
es a research agenda for childhood diarrhoea beyond 2015 
[2–4,11]. The results of their very comprehensive CHNRI 
process, with the timeline extended 15 years ahead and an 
expanded scope of research on preventing morbidity, have 
been published recently[12]. The purpose of this exercise 
was to further contribute to the active field of setting re-
search priorities for childhood diarrhoea, by reviewing the 
landscape of new ideas and/or novel potential interventions 
– hereby referred to as “emerging interventions” – and set 
priorities for investments in their development.
The second level of priority was assigned to 
probiotics and prebiotics; combination vac-
cine for Cryptosporidium, Shigella and en-
terotoxigenic Escherichia coli (ETEC); and to 
the use of anti-emetics in case management. 
The lowest level of enthusiasm was ex-
pressed towards the treatment or prevention 
(vaccines) of environmental enteropathy, 
CFTR inhibitors, and the inhibitors of intesti-
nal epithelial secretion in the treatment of di-
arrhoea. The exercise suggested that there 
are relatively few novel or feasible interven-
tions in the course of development to ad-
dress the high residual disease burden of di-
arrhoea in children.
EmERgINg INTERVENTIONS AgAINST 
CHIldHOOd dIARRHOEA
The 10 emerging interventions were chosen for evaluation 
from the results of a previous CHNRI exercise [12] and fur-
ther consultation with a paediatric gastroenterologist (Ta-
ble 1).The previous exercise [12] brought together 10 
teams, corresponding to research avenues in childhood di-
arrhoeal disease. Each team separately generated and 
ranked their set of research questions. While one team fo-
cused specifically on emerging interventions, many teams 
generated research priorities related to emerging interven-
tions and thus, we considered novel interventions pro-
posed by all teams for inclusion in this exercise. We aimed 
to be open–minded and inclusive in the selection of these 
interventions, appreciating that some of them may still 
need considerable work before being ready for implemen-
tation.
ExPERT OPINION ExERCISE
The CHNRI methodology for priority setting in invest-
ments in health research and technologies was proposed as 
a systematic tool that can be used to develop research pol-
icy and/or prioritize investments in health research [13–
14]. The CHNRI method consists of the following steps: (i) 
investors and policy–makers define the context of the prob-
lem and identify the criteria for priority–setting; (ii) tech-
nical experts generate research priorities and score them 
against the pre–defined criteria; and, (iii) other stakehold-
ers decide on the weight of the criteria, intended to reflect 
a wider societal system of values. The method has been de-
scribed elsewhere, and many examples of implementation 
have been published [15–18].
A group of 12 leading international experts were invited to 
participate in the expert opinion exercise. The group was in-
structed to use a downstream (ie, broad, long–term) ap-
proach and focus solely on emerging interventions. During 
October 2012 the group ranked 10 emerging interventions 
according to a number of criteria used to identify priorities 
for research support in the area of childhood diarrhoea. A 
Table 1. The consolidated list of 10 emerging interventions against childhood diarrhoea
  1. Probiotics and prebiotics
  2. Anti–emetics
  3. Treatment or prevention (vaccines) of environmental enteropathy
  4. Sustainable, affordable latrine options
  5. Household– or community–level water treatment
  6. CFTR inhibitors
  7. Inhibitors of intestinal epithelial function in the treatment of diarrhoea
  8. Antibiotic therapy of Cryptosporidium diarrhoea
  9. Oral or transcutaneous vaccine development
10. Combination vaccine for Cryptosporidium, Shigella, and enterotoxigenic Escherichia coli (ETEC)
CFTR – cystic fibrosis transmembrane conductance regulator
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modified version of CHNRI’s conceptual framework (Table 
2) was used and included 12 criteria for prioritization of 
emerging interventions: 1) answerability (in an ethical way); 
2) low development cost; 3) low product cost; 4) low imple-
mentation cost; 5) predicted efficacy; 6) likelihood of deliv-
erability; 7) likelihood of affordability; 8) likelihood of sus-
tainability; 9) maximum potential impact on mortality 
burden reduction; 10) likelihood of acceptability to health 
workers; 11) likelihood of acceptability to end users; 12) 
predicted impact on equity [19].
All experts invited to participate in the exercise received a 
brief (1 page) background document containing informa-
tion on each of the 10 emerging interventions. This docu-
ment also explained why each of the 12 criteria was chosen 
and how to apply them to each emerging intervention. The 
experts were free to challenge all information provided to 
them in a background document and to share further per-
sonal knowledge or opinion with the group. The experts 
were invited by e–mail to score, independently of each oth-
er, all emerging interventions according to the 12 agreed 
CHNRI criteria.
The scoring of the emerging interventions was conducted 
using a points system that assigned a value of 1 to positive 
answers (yes) and 0 to negative answers (no). When an ex-
pert assigned the answer “undecided” to a given criteria, 
the value of 0.5 points was used. Conversely, when the ex-
pert declared to be insufficiently informed on a given issue 
to answer the question, the input was deemed missing and 
not scored (or penalized). Each research question/theme 
received a score for all 12 criteria from each expert and the 
final score was calculated as the average of the ratios of the 
sum of all points given over the maximum possible num-
ber of points (excluding missing inputs). Such final score 
ranged from 0 to 100% and represents a direct measure of 
‘collective optimism’ for a given emerging intervention.
In the initial exercise, we included different components of 
the cost (development cost, product cost, implementation 
cost and affordability), but those 4 criteria are in fact a sin-
gle criterion (cost). We therefore decided to exclude 3 cri-
teria to ensure the remaining criteria were relatively inde-
pendent of one another (similar to principal component 
analysis). If all 4 were kept in the exercise, this would give 
Table 2. Specific questions used to assess whether the proposed research themes (eg, emerging interventions) satisfy the 12 priority–
setting criteria
1. Answerability in an ethical way (“1” for Yes;“0” for No;“0.5” for Undecided)
• Do we have a sufficient research and development capacity to make the intervention available on the market by 2025?
• Do we have a sufficient level of funding support to make the intervention available on the market by 2025?
• Would you say that it is likely that the remaining technical hurdles can be overcome to make the intervention available on the market by 2025?
2. Low development cost(“1” for Yes;“0” for N;“0.5” for Undecided)
• How much will it cost to get from the current stage of development to commercial availability of each emerging intervention below?
a. <US$ 1 billion
b. <US$ 500 million
c. <US$ 100 million
3. Low product cost(“1” for Yes;“0” for N;“0.5” for Undecided)
• Is it likely to be a low–cost intervention (ie,  <US$ 3.50 per unit?)
4. Low implementation cost(“1” for Yes; “0” for N; “0.5” for Undecided)
• Can we use the existing delivery mechanisms without major modifications (eg, training, infrastructure)?
5. Affordability(“1” for Yes; “0” for N; “0.5” for Undecided)
• Is achievement of a near–universal coverage likely to be affordable to most developing countries?
6. Predicted efficacy (0–100%)
•  Please assess the likelihood (0–100%) that adequately powered randomized controlled trials of the interventions conducted in developing coun-
tries would consistently show statistically significant reduction in cause–specific mortality from childhood diarrhoea.
7. Likely maximum potential impact on mortality burden
•  Please predict the proportion of deaths in children under 5 years of age due to diarrhoea that could be averted if the complete coverage with the 
emerging interventions listed below could be achieved?
8–9. Deliverability and Sustainability (“1” for Yes;“0” for N;“0.5” for Undecided)
•  Taking into account (i) the infrastructure and resources required to deliver emerging interventions listed below (eg, human resources, health fa-
cilities, communication and transport infrastructure); (ii) the resources likely to be available to implement the emerging interventions at the time 
of introduction; (iii) overall capacity of the governments (eg, adequacy of government regulation, monitoring and enforcement; governmental in-
tersectoral coordination), and (iv) internal and external partnership required for delivery of interventions (eg, partnership with civil society and 
external donor agencies), would you say that the emerging interventions would be:
a. Deliverable at the time of introduction?
b. Sustainable for at least 10 years after the time of introduction?
10–12. Acceptability to health workers; Acceptability to end–users; and Impact on equity (“1” for Yes;“0” for N;“0.5” for Undecided)
•  Taking into account the overall context, intervention complexity, health workers’ behaviour and the end–user population at the time of introduc-
tion,
a. Would health workers be likely to comply with implementation guidelines?
b. Would end–users be likely to fully accept the intervention?
c. Would you say that the proposed intervention has the overall potential to improve equity after 10 years following the introduction?
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an undue four–fold “weight” to one criterion at the expense 
of the others. The experts agreed that the most important 
of the 4 cost–related criteria related to emerging interven-
tions is “development cost”, because costs of product and 
implementation can be met through other mechanisms 
(such as GAVI, PEPFAR, Global Fund, etc.). Thus, the cost 
of product, cost of implementation and affordability were 
kept out of the final score calculation. After the exclusion, 
mean scores given to each criterion by the experts was cal-
culated. The overall research priority score (RPS) was cal-
culated as a mean of the 9 intermediate criteria scores. The 
scores given to all 10 emerging interventions are presented 
in Table 3.
mAIN FINdINgS
As shown in Table 3, the panel declared most of their col-
lective optimism towards developing household– or com-
munity–level water treatment, followed by sustainable, af-
fordable latrine options. The key strengths of those 
interventions were high likelihood of efficacy, acceptability 
both among health workers and end–users, and positive 
impact on equity in the population. Those two interven-
tions were followed by antibiotic therapy for Cryptosporid-
ium diarrhoea, and oral or transcutaneous enteric vaccine 
development. These two emerging interventions had simi-
lar scores as the two top–ranked, but their impact on eq-
uity in the population was deemed less certain.
The second priority level was assigned to probiotics and 
prebiotics; combination vaccine for Cryptosporidium, Shi-
gella, and enterotoxigenic Escherichia coli (ETEC); and the 
use of anti–emetics in diarrhoea case management. The key 
weaknesses of the combination vaccine were uncertain an-
swerability and high predicted cost of development, while 
the key uncertainty over the use of probiotics and anti–
emetics is related to very low optimism towards their po-
tential for the reduction of the overall burden of diarrhoea.
The lowest level of optimism was expressed towards the 
treatment or prevention of environmental enteropathy, cystic 
Table 3. The results of the CHNRI exercise: 10 emerging interventions with 9 intermediate scores and an overall research priority score 
(RPS)
Rank Emerging  intervention Answerability
Low  
development 
cost
Likelihood 
of efficacy
Max 
burden 
reduction 
potential
DeliverableSustainable
Acceptable 
to health 
workers
Acceptable 
to end 
users
Impact 
on 
equity
Research 
investment 
priority 
score
1
Household– or commu-
nity–level water treatment
78 47 100 44 68 77 95 86 100 77.3
2 Sustainable, affordable latrine options 64 60 95 45 41 86 91 95 91 74.4
3 Antibiotic therapy of Cryptosporidium diarrhoea 72 49 82 23 64 77 86 91 70 68.2
4 Oral or transcutaneous vaccine development 44 36 77 39 64 64 100 95 82 66.9
5 Probiotics and prebiotics 74 54 60 10 59 86 77 86 64 63.5
6
Cryptosporidium, Shigella, 
and enterotoxigenic 
Escherichia coli (ETEC)
42 29 82 33 55 68 100 86 73 63.1
7 Anti–emetics 65 50 59 7 64 67 91 95 45 60.4
8
Treatment or prevention 
(vaccines) of environmen-
tal enteropathy
29 53 41 39 45 41 80 60 60 49.9
9 CFTR inhibitors 35 42 55 9 15 30 61 61 28 37.4
10
Inhibitors of intestinal ep-
ithelial function in the 
treatment of diarrhoea
38 36 45 21 36 36 44 56 39 39.1
 CFTR – cystic fibrosis transmembrane conductance regulator
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fibrosis transmembrane conductance regulator (CFTR) in-
hibitors, and the use of inhibitors of intestinal epithelial func-
tion in the treatment of diarrhoea. These three interventions 
had uncertain answerability and effectiveness, with low 
scores on deliverability, sustainability and acceptability. 
These interventions were also deemed to have negative im-
pact on equity following their implementation (Table 3).
CONCluSION
In contrast to very large significance that childhood diar-
rhoea still has as a public health problem in low and middle 
income countries, this exercise suggested that relatively few 
novel interventions can be considered feasible at this point. 
The experts were most optimistic about the potential for 
Water and Sanitation Hygiene (WASH) interventions to be 
efficacious and reduce inequities. Although there are high 
development costs associated with most of the emerging 
interventions, investments in this sector will help reduce 
inequities and reduce the burden of childhood diarrhoea. 
In synergy with powerful interventions that are currently 
available, diarrhoeal mortality could be significantly re-
duced in the next 15 years.
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